-DOCSTART- -X- O
The -X- _ O
coronaviruses -X- _ O
( -X- _ O
CoVs -X- _ O
) -X- _ O
are -X- _ O
enveloped -X- _ O
viruses -X- _ O
of -X- _ O
animals -X- _ O
and -X- _ O
humans -X- _ O
associated -X- _ O
mostly -X- _ O
with -X- _ O
enteric -X- _ O
and -X- _ O
respiratory -X- _ O
diseases -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
the -X- _ O
severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
and -X- _ O
10â€“20 -X- _ O
% -X- _ O
of -X- _ O
all -X- _ O
common -X- _ O
colds. -X- _ O
A -X- _ O
subset -X- _ O
of -X- _ O
CoVs -X- _ O
uses -X- _ O
the -X- _ O
cell -X- _ O
surface -X- _ O
aminopeptidase -X- _ B-Intervention
N -X- _ I-Intervention
( -X- _ I-Intervention
APN -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
a -X- _ O
membrane- -X- _ O
bound -X- _ O
metalloprotease -X- _ O
, -X- _ O
as -X- _ O
a -X- _ O
cell -X- _ O
entry -X- _ O
receptor. -X- _ O
In -X- _ O
these -X- _ O
viruses -X- _ O
, -X- _ O
the -X- _ O
envelope -X- _ O
spike -X- _ O
glycoprotein -X- _ O
( -X- _ O
S -X- _ O
) -X- _ O
mediates -X- _ O
the -X- _ O
attachment -X- _ O
of -X- _ O
the -X- _ O
virus -X- _ O
particles -X- _ O
to -X- _ O
APN -X- _ O
and -X- _ O
subsequent -X- _ O
cell -X- _ O
entry -X- _ O
, -X- _ O
which -X- _ O
can -X- _ O
be -X- _ O
blocked -X- _ O
by -X- _ O
neutralizing -X- _ O
antibodies. -X- _ O
Here -X- _ O
we -X- _ O
describe -X- _ O
the -X- _ O
crystal -X- _ O
structures -X- _ O
of -X- _ O
the -X- _ O
receptor-binding -X- _ O
domains -X- _ O
( -X- _ O
RBDs -X- _ O
) -X- _ O
of -X- _ O
two -X- _ O
closely -X- _ O
related -X- _ O
CoV -X- _ O
strains -X- _ O
, -X- _ O
transmissible -X- _ B-Patient
gastroenteritis -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
TGEV -X- _ I-Patient
) -X- _ I-Patient
and -X- _ I-Patient
porcine -X- _ I-Patient
respiratory -X- _ I-Patient
CoV -X- _ I-Patient
( -X- _ I-Patient
PRCV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
in -X- _ O
complex -X- _ O
with -X- _ O
their -X- _ O
receptor -X- _ O
, -X- _ O
porcine -X- _ B-Intervention
APN -X- _ I-Intervention
( -X- _ I-Intervention
pAPN -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
with -X- _ I-Intervention
a -X- _ I-Intervention
neutralizing -X- _ I-Intervention
antibody. -X- _ I-Intervention
The -X- _ O
data -X- _ O
provide -X- _ O
detailed -X- _ O
information -X- _ O
on -X- _ O
the -X- _ O
architecture -X- _ O
of -X- _ O
the -X- _ O
dimeric -X- _ O
pAPN -X- _ O
ectodomain -X- _ O
and -X- _ O
its -X- _ O
interaction -X- _ O
with -X- _ O
the -X- _ O
CoV -X- _ O
S. -X- _ O
We -X- _ O
show -X- _ O
that -X- _ O
a -X- _ O
protruding -X- _ B-Outcome
receptor-binding -X- _ I-Outcome
edge -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
S -X- _ I-Outcome
determines -X- _ I-Outcome
virus-binding -X- _ I-Outcome
specificity -X- _ I-Outcome
for -X- _ I-Outcome
recessed -X- _ I-Outcome
glycan-containing -X- _ I-Outcome
surfaces -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
membrane-distal -X- _ I-Outcome
region -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
pAPN -X- _ I-Outcome
ectodomain. -X- _ I-Outcome
Comparison -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
RBDs -X- _ I-Outcome
of -X- _ I-Outcome
TGEV -X- _ I-Outcome
and -X- _ I-Outcome
PRCV -X- _ I-Outcome
to -X- _ I-Outcome
those -X- _ I-Outcome
of -X- _ I-Outcome
other -X- _ I-Outcome
related -X- _ I-Outcome
CoVs -X- _ I-Outcome
, -X- _ I-Outcome
suggests -X- _ I-Outcome
that -X- _ I-Outcome
the -X- _ I-Outcome
conformation -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
S -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
region -X- _ I-Outcome
determines -X- _ I-Outcome
cell -X- _ I-Outcome
entry -X- _ I-Outcome
receptor -X- _ I-Outcome
specificity. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
edge -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
major -X- _ I-Outcome
antigenic -X- _ I-Outcome
determinant -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
TGEV -X- _ I-Outcome
envelope -X- _ I-Outcome
S -X- _ I-Outcome
that -X- _ I-Outcome
is -X- _ I-Outcome
targeted -X- _ I-Outcome
by -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
provide -X- _ O
a -X- _ O
compelling -X- _ O
view -X- _ O
on -X- _ O
CoV -X- _ B-Patient
cell -X- _ B-Intervention
entry -X- _ I-Intervention
and -X- _ I-Intervention
immune -X- _ I-Intervention
neutralization -X- _ I-Intervention
, -X- _ O
and -X- _ O
may -X- _ O
aid -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
antivirals -X- _ O
or -X- _ O
CoV -X- _ O
vaccines. -X- _ O
APN -X- _ B-Intervention
is -X- _ O
also -X- _ O
considered -X- _ O
a -X- _ O
target -X- _ O
for -X- _ O
cancer -X- _ O
therapy -X- _ O
and -X- _ O
its -X- _ O
structure -X- _ O
, -X- _ O
reported -X- _ O
here -X- _ O
, -X- _ O
could -X- _ O
facilitate -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
anti-cancer -X- _ O
drugs -X- _ O
. -X- _ O

